Matches in SemOpenAlex for { <https://semopenalex.org/work/W3144733335> ?p ?o ?g. }
- W3144733335 endingPage "723" @default.
- W3144733335 startingPage "712" @default.
- W3144733335 abstract "Identifying the most effective first-line treatment for metastatic renal cell carcinoma (mRCC) is challenging as rapidly evolving data quickly outdate the existing body of evidence, and current approaches to presenting the evidence in user-friendly formats are fraught with limitations.To maintain living evidence for contemporary first-line treatment for previously untreated mRCC.We have created a living, interactive systematic review (LISR) and network meta-analysis for first-line treatment of mRCC using data from randomized controlled trials comparing contemporary treatment options with single-agent tyrosine kinase inhibitors. We applied an advanced programming and artificial intelligence-assisted framework for evidence synthesis to create a living search strategy, facilitate screening and data extraction using a graphical user interface, automate the frequentist network meta-analysis, and display results in an interactive manner.As of October 22, 2020, the LISR includes data from 14 clinical trials. Baseline characteristics are summarized in an interactive table. The cabozantinib + nivolumab combination (CaboNivo) is ranked the highest for the overall response rate, progression-free survival, and overall survival, whereas ipilimumab + nivolumab (NivoIpi) is ranked the highest for achieving a complete response (CR). NivoIpi, and atezolizumab + bevacizumab (AteBev) were ranked highest (lowest toxicity) and CaboNivo ranked lowest for treatment-related adverse events (AEs). Network meta-analysis results are summarized as interactive tables and plots, GRADE summary-of-findings tables, and evidence maps.This innovative living and interactive review provides the best current evidence on the comparative effectiveness of multiple treatment options for patients with untreated mRCC. Trial-level comparisons suggest that CaboNivo is likely to cause more AEs but is ranked best for all efficacy outcomes, except NivoIpi offers the best chance of CR. Pembrolizumab + axitinib and NivoIpi are acceptable alternatives, except NivoIpi may not be preferred for patients with favorable risk. Although network meta-analysis provides rankings with statistical adjustments, there are inherent biases in cross-trial comparisons with sparse direct evidence that does not replace randomized comparisons.It is challenging to decide the best option among the several treatment combinations of immunotherapy and targeted treatments for newly diagnosed metastatic kidney cancer. We have created interactive evidence summaries of multiple treatment options that present the benefits and harms and evidence certainty for patient-important outcomes. This evidence is updated as soon as new studies are published." @default.
- W3144733335 created "2021-04-13" @default.
- W3144733335 creator A5001408270 @default.
- W3144733335 creator A5005768868 @default.
- W3144733335 creator A5008572738 @default.
- W3144733335 creator A5017952355 @default.
- W3144733335 creator A5018306647 @default.
- W3144733335 creator A5020818764 @default.
- W3144733335 creator A5027449919 @default.
- W3144733335 creator A5030233600 @default.
- W3144733335 creator A5031306593 @default.
- W3144733335 creator A5034715033 @default.
- W3144733335 creator A5035431515 @default.
- W3144733335 creator A5038200586 @default.
- W3144733335 creator A5045921324 @default.
- W3144733335 creator A5057735964 @default.
- W3144733335 creator A5058650905 @default.
- W3144733335 creator A5065058975 @default.
- W3144733335 creator A5067550666 @default.
- W3144733335 creator A5068639858 @default.
- W3144733335 creator A5073960684 @default.
- W3144733335 creator A5074582149 @default.
- W3144733335 creator A5082402405 @default.
- W3144733335 creator A5085185987 @default.
- W3144733335 date "2021-12-01" @default.
- W3144733335 modified "2023-10-13" @default.
- W3144733335 title "A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma" @default.
- W3144733335 cites W1717153315 @default.
- W3144733335 cites W2037593179 @default.
- W3144733335 cites W2040557955 @default.
- W3144733335 cites W2111999709 @default.
- W3144733335 cites W2116949558 @default.
- W3144733335 cites W2151225337 @default.
- W3144733335 cites W2157076786 @default.
- W3144733335 cites W2222086386 @default.
- W3144733335 cites W2339783374 @default.
- W3144733335 cites W2400379639 @default.
- W3144733335 cites W2468996569 @default.
- W3144733335 cites W2520714999 @default.
- W3144733335 cites W2557678736 @default.
- W3144733335 cites W2558408743 @default.
- W3144733335 cites W2604568423 @default.
- W3144733335 cites W2606304149 @default.
- W3144733335 cites W2766211624 @default.
- W3144733335 cites W2789468111 @default.
- W3144733335 cites W2790729376 @default.
- W3144733335 cites W2792937256 @default.
- W3144733335 cites W2797935388 @default.
- W3144733335 cites W2801270371 @default.
- W3144733335 cites W2804772768 @default.
- W3144733335 cites W2805302875 @default.
- W3144733335 cites W2894278684 @default.
- W3144733335 cites W2897161734 @default.
- W3144733335 cites W2903640204 @default.
- W3144733335 cites W2907028960 @default.
- W3144733335 cites W2909056931 @default.
- W3144733335 cites W2911812451 @default.
- W3144733335 cites W2913745075 @default.
- W3144733335 cites W2915456024 @default.
- W3144733335 cites W2943887705 @default.
- W3144733335 cites W2947020554 @default.
- W3144733335 cites W2967350775 @default.
- W3144733335 cites W2969242120 @default.
- W3144733335 cites W2977743112 @default.
- W3144733335 cites W2988263178 @default.
- W3144733335 cites W2993549922 @default.
- W3144733335 cites W2994968455 @default.
- W3144733335 cites W2996068609 @default.
- W3144733335 cites W3009192693 @default.
- W3144733335 cites W3010374839 @default.
- W3144733335 cites W3014717122 @default.
- W3144733335 cites W3018979351 @default.
- W3144733335 cites W3027236841 @default.
- W3144733335 cites W3031307765 @default.
- W3144733335 cites W3031942086 @default.
- W3144733335 cites W3044336467 @default.
- W3144733335 cites W3046396978 @default.
- W3144733335 cites W3047001933 @default.
- W3144733335 cites W3080692347 @default.
- W3144733335 cites W3088188638 @default.
- W3144733335 doi "https://doi.org/10.1016/j.eururo.2021.03.016" @default.
- W3144733335 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33824031" @default.
- W3144733335 hasPublicationYear "2021" @default.
- W3144733335 type Work @default.
- W3144733335 sameAs 3144733335 @default.
- W3144733335 citedByCount "40" @default.
- W3144733335 countsByYear W31447333352021 @default.
- W3144733335 countsByYear W31447333352022 @default.
- W3144733335 countsByYear W31447333352023 @default.
- W3144733335 crossrefType "journal-article" @default.
- W3144733335 hasAuthorship W3144733335A5001408270 @default.
- W3144733335 hasAuthorship W3144733335A5005768868 @default.
- W3144733335 hasAuthorship W3144733335A5008572738 @default.
- W3144733335 hasAuthorship W3144733335A5017952355 @default.
- W3144733335 hasAuthorship W3144733335A5018306647 @default.
- W3144733335 hasAuthorship W3144733335A5020818764 @default.
- W3144733335 hasAuthorship W3144733335A5027449919 @default.
- W3144733335 hasAuthorship W3144733335A5030233600 @default.